AMS

Business Context and Reporting Period

Company: American Shared Hospital Services (ASHS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Model: ASHS provides Gamma Knife stereotactic radiosurgery services to medical centers through its 81% owned subsidiary, GK Financing, LLC (GKF). The remaining 19% interest is held by Elekta AG, the equipment manufacturer. Revenue is generated via "fee per use" or "revenue sharing" contracts. As of December 31, 2004, the company operated 18 Gamma Knife units across 17 states, with 100% of revenue derived from this segment.

Key Financial Metrics (Year Ended Dec 31, 2004)

Margins: Operating margin was approximately 20.0% in 2004 compared to 18.4% in 2003. Net profit margin improved to 12.1% in 2004 from 8.5% in 2003.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 1.3% to $16.4 million, driven by the addition of one new Gamma Knife unit in 2004 and full-year inclusion of three units added in 2003. This offset a 14% revenue decline at units operating for more than one year.
• Profitability: Net income rose 43.6% to $1.99 million. This was primarily due to a $375,000 reduction in income tax expense (driven by a $547,000 tax benefit from stock option exercises) and lower selling/administrative costs.
• Costs: Costs of operations increased 6.6% to $7.9 million, largely due to depreciation on new units and expired warranties on older units. Selling and administrative expenses decreased 9.0% due to lower payroll and business development costs.
• Liquidity: Cash and cash equivalents decreased by $2.2 million, primarily due to debt principal payments ($7.4 million) and dividend distributions ($0.7 million), partially offset by strong operating cash flow.

Outlook, Risks, and Management Commentary

• Expansion: The company had two sites under development as of March 2005, with one (Baptist Hospital of East Tennessee) becoming operational in January 2005. Two additional sites were scheduled to commence operations in 2005.
• Financing Risks: The business is capital intensive. The primary lender, DVI Financial Services, filed for Chapter 11 bankruptcy in 2003. While loans were assumed by a successor servicer and the company has secured financing for current projects, there is no assurance future financing will be available on acceptable terms.
• Reimbursement Risk: Revenue is sensitive to Medicare and third-party payer reimbursement rates. Changes in the Ambulatory Product Classifications (APC) system have previously reduced revenue at certain sites. The company faces risk if reimbursement rates decline or if procedure volumes fall short of projections.
• Technology Risk: The company faces potential obsolescence risks as Elekta introduces upgraded models (e.g., Model 4C). Upgrading existing units is estimated to cost between $200,000 and $1,000,000 per unit.
• Regulatory Risk: The company is subject to federal anti-kickback statutes, Stark II laws regarding physician self-referrals, and Certificate of Need (CON) requirements in various states.

Investor Verification Checklist

• Debt Servicing: Verify the company's ability to service $25.5 million in long-term debt, particularly given the history of its primary lender's bankruptcy.
• Reimbursement Trends: Monitor Medicare and private payer reimbursement rates for Gamma Knife procedures, as rate reductions directly impact revenue sharing contracts.
• Unit Utilization: Assess the volume of procedures at existing sites, noting the reported 14% revenue decline at mature units in 2004.
• Capital Expenditures: Confirm the funding status for the two sites under development and the estimated costs for upgrading existing units to the Model 4C standard.
• Minority Interest: Review the 19% minority interest held by Elekta AG and the associated cash distribution requirements ($399,000 distributed in 2004).